RTW Investments’s Apellis Pharmaceuticals APLS Stock Holding History

RTW Investments’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-3,685,045	Closed	-$148M	–	86
2026 Q1	$148M	Sell	3,685,045 -3,981,719	-52%	-$85.8M	1.48%	21
2025 Q4	$193M	Buy	+7,666,764	New	+$180M	1.93%	13
2022 Q2	–	Sell	-51,194	Closed	-$2.6M	–	109
2022 Q1	$2.6M	Sell	51,194 -1,939,210	-97%	-$85.6M	0.05%	89
2021 Q4	$94.1M	Buy	+1,990,404	New	+$78.4M	1.37%	25

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

RTW Investments's APLS Position: Q2 2026 in Review

RTW Investments sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 3,685,045 shares — an estimated $148M sold.

RTW Investments first reported a position in APLS in Q4 2021 and held it in 4 quarters. The position peaked at $193M in Q4 2025. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

RTW Investments reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
RTW Investments sold 3,685,045 Apellis Pharmaceuticals shares in Q2 2026, an estimated $148M.
RTW Investments first reported a position in Apellis Pharmaceuticals in Q4 2021 and held it in 4 quarters.
RTW Investments's Apellis Pharmaceuticals position peaked at $193M in Q4 2025.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on RTW Investments's 13F filing for Q2 2026, filed 14 Aug 2026.